Cue Biopharma, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Cue Biopharma, Inc. (CUE) had Operating Lease, Weighted Average Discount Rate, Percent of 9.75% as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-14
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 9.75%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 9.75%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 9.77%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 9.78%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2026-06-30 | 9.75% 10-Q · filed 2026-08-14 | |
| 2026-03-31 | 9.75% 10-Q · filed 2026-05-14 | |
| 2025-12-31 | 9.77% 10-Q · filed 2026-08-14 | |
| 2025-09-30 | 9.78% 10-Q · filed 2025-11-12 | |
| 2025-06-30 | 9.78% 10-Q · filed 2025-08-12 | |
| 2025-03-31 | 6.88% 10-Q · filed 2025-05-12 | |
| 2024-12-31 | 6.25% 10-K · filed 2026-03-16 | 6.85% 10-K · filed 2025-03-31 |
| 2024-09-30 | 5.96% 10-Q · filed 2024-11-14 | |
| 2024-06-30 | 6.09% 10-Q · filed 2024-08-14 | |
| 2024-03-31 | 6.18% 10-Q · filed 2024-05-09 | |
| 2023-12-31 | 6.25% 10-K · filed 2025-03-31 | |
| 2023-09-30 | 5.75% 10-Q · filed 2023-11-03 | |
| 2022-12-31 | 6.41% 10-K · filed 2024-03-28 | |
| 2022-06-30 | 5.75% 10-Q · filed 2022-08-04 | |
| 2022-03-31 | 5.50% 10-Q · filed 2022-05-10 | |
| 2021-09-30 | 6.00% 10-Q · filed 2021-11-09 | |
| 2021-06-30 | 6.00% 10-Q · filed 2021-08-09 | |
| 2020-09-30 | 6.00% 10-Q · filed 2020-11-09 | |
| 2020-06-30 | 6.00% 10-Q · filed 2020-08-07 | |
| 2020-03-31 | 6.00% 10-Q · filed 2021-05-10 | |
| 2019-09-30 | 6.00% 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |